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interactions and strategic relationships between the 
societies. The MoU will facilitate collaboration across the 
ocean on e.g. Joint Task Groups, Scientific meetings and 
Education. The development of reports (e.g. AAPM task group 
reports, professional guidelines, etc.) should seek 
collaboration between the two societies where appropriate 
and feasible. Such collaboration could be achieved by inviting 
joint membership on appropriate drafting task groups by the 
initiating society. Both societies have now Standard 
Operating Procedures (SOP) available for development of 
guidelines, which gives a good structure for initiating 
international guidelines and securing high quality reviews - 
representing both Europe and North America – in upcoming 
guidelines. 
 
Proffered Papers: Radiobiology 5: Imaging and molecular 
biomarkers in radiation oncology  
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Noninvasive imaging of the PD-1/PD-L1 checkpoint in naïve 
mice and after combined radioimmunotherapy 
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1, F. Braun2, G. Niedermann1 
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Purpose or Objective: There is increasing evidence that 
antibodies blocking the PD-1 checkpoint (either anti-PD-1 or 
anti-PD-L1) dramatically increase in-field anti-tumor 
responses to ionizing radiation and enhance abscopal effects 
on non-irradiated metastases. Here, we developed PET 
tracers based on therapeutic surrogate antibodies that 
enable to non-invasively visualize not only the PD-1 and PD-
L1 expression in mice but also the biodistribution of the 
surrogate checkpoint-blocking antibodies. 
 
Material and Methods: Two novel PET tracers were 
developed by conjugation of anti-murine PD-1 and PD-L1 
surrogate checkpoint-blocking antibodies with the chelator 
NOTA and labeling with the radioisotope 64Cu. Non-invasive 
PET imaging was performed on naïve and tumor-bearing 
mice. Mice bearing s.c. B16 melanomas were treated with 
hypofractionated radiation therapy (hRT) using two fractions 
of 12 Gy in combination with CTLA-4 checkpoint blockade 
several days before PET imaging. PD-1 or PD-L1 knockout 
mice and PD-L1-deficient B16 cells generated using the 
CRISPR/Cas technology served as specificity controls. 
 
Results: The newly developed PD-1 and PD-L1 PET tracers 
allowed the highly specific and high-resolution imaging of PD-
1 and PD-L1 expression and of the biodistribution of the two 
therapeutic antibodies in both naïve and tumor-bearing mice 
treated with hRT and CTLA-4 checkpoint blockade. Imaging 
of the respective knockout mice, blocking experiments with 
an excess amount of unlabeled antibodies, and the analysis of 
animals bearing both wild-type B16 melanomas and PD-L1-
CRISPR knockout melanomas demonstrated the high 
specificity of the two newly developed PET tracers. The in 
vivo imaging data were confirmed by ex vivo biodistribution 
analyses. The targets of the PET tracer antibodies were 
verified by ex vivo flow cytometric analyses of tumor single-
cell suspensions and cell suspensions of secondary lymphoid 
and other organs. Interestingly, visualization of immune-
related adverse events was also possible. 
 
Conclusion: We developed two innovative PET tracers that 
allow imaging the expression of the receptor/ligand pair of 
the important PD-1 checkpoint and the biodistribution of 
surrogate checkpoint-blocking antibodies in fully 
immunocompetent mice. This technology also enabled whole-
body pictures of combination radio/immunotherapies. 
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Purpose or Objective: Objectives: Aerobic glycolysis is the 
main pathway of energy production in tumors (Warburg 
effect), and ionizing radiation is reported to switch this to 
mitochondrial oxidative phosphorylation. We developed a 
novel PET probe,18F-2-tert-butyl-4-chloro-5- {6-[2-(2-fluoro-
ethoxy)-ethoxy]-pyridin-3-ylmethoxy}-2H-pyridazin-3-one 
(18F-BCPP-EF), for imaging mitochondrial complex I (MC-I) 
activity. In this study, early detection of tumor 
radiotherapeutic effect was evaluated using 18F-BCPP-EF and 
compared with 18F-FDG and apoptosis index. 
 
Material and Methods: Methods: Tumor uptake of 18F-BCPP-
EF or 18F-FDG was examined in C3H/HeN mice inoculated 
with murine squamous cell carcinoma SCCVII after a single 
dose of x-ray irradiation, 0, 6, 15, or 30 Gy. Apoptosis 
incidence was determined by TUNEL staining in excised tumor 
tissue. 
 
Results: Results: Tumor growth suppression was dose-
dependent; tumor grew 10 fold (0 Gy), 5 fold (6 Gy), 2 fold 
(15 Gy), and reduced to half in its volume (30 Gy) 14 days 
after treatment. 18F-BCPP-EF uptake was significantly 
increased as early as 2 days (15 Gy) or 3 days (30 Gy) after 
irradiation, at time points when tumor size or apoptosis index 
showed no difference among radiation doses. In contrast, 
18F-FDG uptake was initially increased dose-dependently, 
remained elevated, and eventually decreased 10 days after 
30 Gy when tumor size was already reduced. Apoptosis index 
was increased after irradiation but failed to correlate with 
tumor response. The uptakes of 18F-BCPP-EF and 18F-FDG, as 
well as AI, were plotted against Tvol on day 14 as surrogate 
of radiotherapeutic effect. Highly significant negative 
correlations were observed between the uptake of 18F-BCPP-
EF and Tvol on day 14, as early as on day 2, and on each day 
up to day 7, and in all days combined. In contrast, between 
tumor uptake of 18F-FDG and Tvol on day 14, there was a 
significant negative correlation on day 2 and positive 
correlations on day 10 and on day 14, with no correlation in 
all days combined. 
 
Conclusion: Conclusion: Tumor uptake of 18F-BCPP-EF was 
increased dose-dependently early after irradiation when 18F-
FDG uptake and apoptosis index remained elevated 
regardless of radiation doses or its efficacy. The results 
suggest that 18F-BCPP-EF is a promising “positive” MC-I 
imaging PET probe for early detection of adequacy of tumor 
radiotherapy.  
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Modelling tissue radiosensitivity and PET hypoxia image 
contrast in acute and chronic hypoxia 
D.R. Warren
1University of Oxford, CRUK/MRC Oxford Institute for 
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Purpose or Objective: PET imaging studies with the hypoxia 
tracer 18F-MISO typically show a heterogeneous distribution 
within the tumour, and regions of high uptake have been 
proposed as targets for dose painting. However, there is no 
widely-accepted method to determine dose prescriptions 
from hypoxia imaging. Oxygen diffusion distances in tissue 
(~100 μm) are smaller than the PET resolution (~4 mm) so a 
range of radiosensitivities may exist within each voxel. 
Furthermore, the perfused vasculature is not constant over 
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the course of a fractionated radiotherapy treatment or during 
a PET study. This work examines how transient perfusion of 
vessels may influence tissue radiosensitivity (including 
reoxygenation) and FMISO image contrast, as a guide for dose 
painting. 
 
Material and Methods: Microscopic oxygen and FMISO 
distributions are simulated in tissue using bespoke MATLAB 
software which solves coupled partial differential equations 
by finite difference methods. Dynamic vasculature is 
modelled by opening and closing individual vessels at 
random, with time spent in each state sampled from a 
normal distribution. Oxygen enhancement ratios are 
calculated from the resulting PO2 maps. The optimal 
prescription dose is found by simulating a range of dose 
levels and determining radiobiological cell kill using the 
linear-quadratic model with repopulation. A novel approach 
to modelling reoxygenation is adopted in which a tissue’s 
oxygen consumption in one fraction is reduced by the cell kill 
in previous fractions. 
 
Results: Predicted FMISO tissue-to-muscle ratios (TMR) are in 
the range 1.0-2.3, increasing as PO2 decreases to a peak at 
~7 mmHg. At very low vascularity, FMISO uptake is limited by 
perfusion of tracer into the tissue, rather than the oxygen-
dependent binding characteristic. No gross differences are 
observed in TMRs simulated with static or dynamic vascular 
models. For a representative hypoxic tumour (10 mmHg, 
intrinsic α=0.3) surviving fractions of 10^-9 are predicted at 
doses of: 110 Gy (static vasculature, no reoxygenation), 87 
Gy (dynamic vasculature changing every fraction) and 71 Gy 
(reoxygenation by reduced consumption). The effect of 
vessel dynamics is negligible if significant reoxygenation of 
chronic hypoxia occurs. 
 
 
 
 
 
Conclusion: A model has been demonstrated that predicts 
realistic FMISO uptake in hypoxic tissue and provides a 
method for calculating prescription doses with 
reoxygenation. Individual vessel dynamics do not affect 
FMISO image contrast at 4 hours, or the prescription dose if 
global reoxygenation occurs. 
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Purpose or Objective: With a 5-year survival rate of 5%, 
pancreatic ductal adenocarcinoma (PDAC) is considered a 
disease of unmet-need. Preclinical radiobiological research in 
PDAC has been limited by mouse models that do not 
recapitulate the human biology and, more importantly, the 
immense technical challenges in establishing a platform that 
enables precise irradiation of pancreatic tumours in mice 
 
Material and Methods: Herein we describe the key steps in 
the development of a state-of-the-art preclinical image-
guided radiotherapy (IGRT) platform that enables precise 
planning and dose delivery in the KRASLSL.G12D/+; 
p53R172H/+; PdxCretg/+ (KPC), a genetically-engineered 
mouse model (GEMM) of PDAC. CT (x-ray computerised 
tomography) does not provide the soft tissue contrast 
required for accurate and precise RT planning in the mouse. 
We demonstrate the use of magnetic resonance Imaging (MRI) 
for RT planning in the mouse abdomen. KPC mice with 
spontaneous pancreatic tumours were anaesthetised and 
placed in an MR-CT compatible cradle. A newly-developed 
respiratory-gated multiple echo contrast scan (8 echoes, TE 
6-50 ms) operating at constant TR=3600, was run at 
150x150x300 um resolution in a scan time of ca. 9 minutes. 
 
Results: Tumours were undetectable using CT but showed as 
bright regions on T2-weighted images, as described 
previously. After registration of the MRI to the CT images RT 
planning was quite straightforward and beam trajectory and 
RT dose estimations were performed for a conical arc 
trajectory. MRI can be used with CT-guided RT system to give 
soft tissue contrast and enable RT planning. The respiratory 
gated T2-weighted scans acquired using multiple echoes gave 
very good contrast, though the scan time was relatively long 
(ca. 9 minutes). At the expense of SNR this can be reduced to 
ca. 2 minutes through use of fast spin echo. The different 
steps will be discussed in detail. Precise beam delivery was 
confirmed using immunohistochemical staining for γH2AX 
foci. 
 
Conclusion: Altogether, our IGRT platform represents a novel 
tool to explore the effects of RT on the biology of PDAC and 
investigate the mechanisms of treatment resistance. To our 
best of knowledge, no studies to date have reported such a 
precise MR-based IGRT platform for preclinical 
radiobiological research in the KPC model. This platform will 
enable exploration of the mechanisms of treatment 
resistance and is expected to provide important 
radiobiological insight to guide successful future clinical trials 
that will directly benefit patients with PDAC. 
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Purpose or Objective: MRI is increasingly used in radiation 
oncology for target delineation and real-time treatment 
guidance. The gadolinium-based nanoparticles (GdNP) used in 
this study are a dual modality probe with MRI contrast and 
radiosensitization properties. We use a mouse model of 
pancreatic cancer to demonstrate in vivo contrast 
enhancement, quantification of GdNP concentration, and 
